{"id":"W4416391581","doi":"10.1016/j.annonc.2025.09.031","title":"LBA21 First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Astellas Pharma; Eisai; Jazz Pharmaceuticals; Chugai Pharmaceutical; Seagen; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Pfizer; Myriad Genetics; AstraZeneca; Eli Lilly and Company","keywords":"Metastatic breast cancer; Chemotherapy; Immunotherapy; Breast cancer; Cancer; Chemotherapy regimen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000909493,0.0009805892,0.001749092,0.0002754768,0.0002136733,0.001018325,0.0006009472,0.0009478845,0.00559195],"category_scores_gemma":[0.001046994,0.0003245933,0.001528885,0.0003484936,0.0006227324,0.0007624389,0.0003195181,0.002665296,0.0008699877],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009781235,"about_ca_system_score_gemma":0.0006907945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001174938,"about_ca_topic_score_gemma":0.004160482,"domain_scores_codex":[0.999684,0.0001682501,0.00001184806,0.00004798722,0.00002109056,0.00006688659],"domain_scores_gemma":[0.9995561,0.0001329288,0.00009707848,0.00003015855,0.00001650991,0.0001670873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9243913,0.004000614,0.001676014,0.0008219765,0.001740796,0.00007317404,0.00008720167,0.001444976,0.005478746,0.0003037884,0.002840106,0.05714134],"study_design_scores_gemma":[0.8436682,0.1368538,0.009893414,0.0001418223,0.001938797,0.000228613,0.0000952254,0.00143395,0.001405413,0.0007462868,0.003559739,0.00003475991],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.985529,0.007508441,0.0002380498,0.001049981,0.0003498428,0.0004552048,0.001268015,0.00008295439,0.003518481],"genre_scores_gemma":[0.986703,0.00427247,0.0005160131,0.00106566,0.0002321096,0.0004979916,0.001928454,0.00002819407,0.004756187],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00559195,"threshold_uncertainty_score":0.01870698,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08251542603776353,"score_gpt":0.4295659143172496,"score_spread":0.3470504882794861,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}